Leon Kujmanian, MD
Endocrinology, Diabetes & Metabolism · Glendale, CANPI 1194827782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 379 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Novo Nordisk at 25.3% of the total. Reporting peaked in 2019 at $2,060 and has fallen 69.1% since, to $636 in 2025.
Across 379 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Dexcom, Inc.$573
- Sanofi-aventis U.S. LLC$467
- Abbott$456
- AstraZeneca$411
- AbbVie$365
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,851100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 111 | $1,736 |
| Dexcom, Inc. | 32 | $573 |
| Sanofi-aventis U.S. LLC | 26 | $467 |
| Abbott | 24 | $456 |
| AstraZeneca | 24 | $411 |
| AbbVie(2 entities) | 17 | $365 |
| Boehringer Ingelheim | 15 | $355 |
| Lilly USA, LLC | 24 | $350 |
| Amgen(2 entities) | 17 | $336 |
| Medtronic(2 entities) | 18 | $320 |
| Mannkind Corporation | 12 | $241 |
| Merck | 13 | $208 |
| Novartis | 4 | $102 |
| Amarin Pharma, Inc. | 5 | $100 |
| BETA Bionics, Inc. | 3 | $72 |
| Cequr Corporation | 1 | $57 |
| Corcept Therapeutics | 3 | $52 |
| BD | 2 | $50 |
| Insulet Corporation | 2 | $49 |
| Nestle Healthcare Nutrition Inc. | 2 | $49 |
| Valeritas, Inc. | 2 | $46 |
| Sequel Med Tech, LLC | 2 | $44 |
| Shire North American Group Inc | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Johnson & Johnson | 1 | $35 |
| Ascensia Diabetes Care US Inc. | 2 | $33 |
| Radius Health, Inc. | 1 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Acerus Pharmaceuticals Corporation | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Vertiflex, Inc. | 1 | $18 |
| GSK | 1 | $12 |
How this compares
$6,865 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 1,233 | $802,472 |
| OzempicSemaglutide | 700 | $699,449 |
| MounjaroTirzepatide | 440 | $475,328 |
| FarxigaDapagliflozin Propanediol | 665 | $431,218 |
| TrulicityDulaglutide | 410 | $419,172 |
| RybelsusSemaglutide | 303 | $338,516 |
| Metformin Er GastricMetformin Hcl | 113 | $231,095 |
| JanuviaSitagliptin Phosphate | 305 | $187,029 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 578 | $180,326 |
| JanumetSitagliptin Phos/Metformin Hcl | 278 | $157,041 |
| TradjentaLinagliptin | 215 | $131,663 |
| DapagliflozinDapagliflozin Propanediol | 187 | $104,382 |
| VascepaIcosapent Ethyl | 216 | $77,286 |
| Tresiba Flextouch U-100Insulin Degludec | 144 | $71,521 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 112 | $62,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,736 | $1,037,9651,003 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Synjardy, Synjardy Xr | $355 | $989,5091,546 claims |
| Lilly USA, LLCMounjaro, Trulicity | $350 | $894,499850 claims |
| AstraZenecaFarxiga | $411 | $431,218665 claims |
| MerckJanuvia, Janumet, Steglatro, Janumet Xr | $208 | $365,931636 claims |
| Johnson & JohnsonInvokana | $35 | $26,42441 claims |
| AmgenProlia | $336 | $21,17613 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $467 | $19,23018 claims |
| AbbVieSynthroid | $365 | $8,527152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Glendale
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.